

FINAL EXAM
JUNE 2018

NATIONAL BOARD OF EXAMINATIONS

RESPIRATORY DISEASES

PAPER-III

RPD/J/18/42/III

Time: 3 hours

Max. Marks:100

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

- | | | |
|-----|---|-----|
| 1. | a) Primary complex
b) Latent tuberculosis | 5+5 |
| 2. | a) Role of corticosteroids in management of tuberculosis.
b) INH mono-resistance: Implications in tuberculosis control. | 5+5 |
| 3. | a) Merits and de-merits of shorter regimens for MDR-TB.
b) Diagnosis and management of hepatitis due to first line anti-tuberculosis drugs. | 5+5 |
| 4. | a) Strategy of prevention of transmission of tuberculosis in health care workers.
b) Causes of secondary drug resistance in TB patients. | 5+5 |
| 5. | a) Complex Sleep apnoea
b) Causes of Central Sleep apnoea. | 5+5 |
| 6. | a) Role of corticosteroids in patients with septic shock.
b) Management of acute exacerbation of COPD in critically ill. | 5+5 |
| 7. | a) Lung protective ventilation.
b) Diagnosis of ventilator associated pneumonia. | 5+5 |
| 8. | a) Fluid therapy in patients with septic shock.
b) Initial antibiotic therapy in patients with septic shock. | 5+5 |
| 9. | a) Causes of difficulty in weaning a patient from mechanical ventilation.
b) Role of non-invasive ventilation for management of chronic respiratory failure. | 5+5 |
| 10. | a) Newer drugs for management of MDR-TB.
b) Challenges of END TB Strategy. | 5+5 |
